#invokana

[amrutatbrc1]

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market 2024 : Size, Growth Rate, Business Module, Product Scope, Regional Analysis And Expansions 2033

The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market: https://www.thebusinessresearchcompany.com/report/sodium-glucose-cotransporter-2-sglt2-inhibitors-global-market-report

According to The Business Research Company’s Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Global Market Report 2024, The sodium glucose cotransporter 2 (SGLT2) inhibitors market size has grown strongly in recent years. It will grow from $9.37 billion in 2023 to $10.17 billion in 2024 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to early clinical trial successes, rising regulatory approvals, increasing diabetes diagnosis rates, and the demand for innovative diabetes treatments.

The sodium glucose cotransporter 2 (SGLT2) inhibitors market size is expected to see strong growth in the next few years. It will grow to $14.19 billion in 2028 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to rising diabetes prevalence, increasing obesity rates, growing awareness of diabetes management, and expanding applications in heart and kidney disease treatments. Major trends in the forecast period include the integration of combination therapies, personalized medicine approaches, technological improvement, and traditional drug development.

The increasing prevalence of diabetes is expected to propel the growth of the sodium glucose cotransporter 2 (SGLT2) inhibitor market going forward. Diabetes refers to a group of metabolic disorders characterized by high blood sugar levels resulting from defects in insulin secretion, insulin action, or both. The rise in diabetes cases can be attributed to factors such as urbanization, stress, environmental pollutants, and a lack of access to healthcare services. Sodium glucose cotransporter 2 (SGLT2) inhibitors are used in diabetes treatment to lower blood glucose levels by preventing glucose reabsorption in the kidneys, leading to its excretion in urine. They also offer cardiovascular and renal benefits, making them a valuable option for managing diabetes and its complications. For instance, in July 2021, according to the International Diabetes Federation, a Belgium-based national diabetes association, the total number of people living with diabetes is expected to increase to 643 million by 2030 and 783 million by 2045. Three out of four adults with diabetes reside in low- and middle-income countries. Therefore, the increasing prevalence of diabetes is driving the growth of the sodium glucose cotransporter 2 (SGLT2) inhibitor market.

Get A Free Sample Of The Report (Includes Graphs And Tables): https://www.thebusinessresearchcompany.com/sample.aspx?id=18473&type=smp

The sodium glucose cotransporter 2 (SGLT2) inhibitors market covered in this report is segmented –

1) By Type: Invokana, Jardiance, Farxiga Or Forxiga, Suglat 2) By Route Of Administration: Oral Route, Other Route Of Administration 3) By End User: Hospitals, Homecare Settings, Clinics

Major companies operating in the sodium glucose cotransporter 2 (SGLT2) inhibitor market are focused on developing dual inhibitor therapeutic solutions to improve patient outcomes and manage blood sugar levels. Dual inhibitor therapeutic solutions refer to treatments that simultaneously target two different sodium-glucose cotransporters (SGLT1 and SGLT2) to enhance efficacy in managing conditions such as heart failure and diabetes. For instance, in May 2023, Lexicon Pharmaceuticals Inc., a US-based biopharmaceutical company, received approval from the Food and Drug Administration (FDA) for sotagliflozin, a treatment for heart failure. This first-in-class dual inhibitor of sodium-glucose cotransporters 1 and 2 is a once-daily tablet designed to reduce cardiovascular death, heart failure hospitalizations, and urgent heart failure visits in adults with heart failure, type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. Its benefits include reduced renal glucose and sodium reabsorption, which leads to preload and afterload reduction and decreased sympathetic activity.

The sodium glucose cotransporter 2 (sglt2) inhibitors market report table of contents includes:

1. Executive Summary

2. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Characteristics

3. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Trends And Strategies

4. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market - Macro Economic Scenario

5. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Size and Growth ............

32. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Competitive Benchmarking

33. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

35. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Future Outlook and Potential Analysis

36. Appendix

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[novaglobalhealthcare]

What Are My Options for Type 2 Diabetes Medications?

There are different types, or classes, of medications that work in different ways to lower blood glucose (also known as blood sugar) levels. Some options are taken by mouth and others are injected. Some of the commonly used classes of non-insulin medications include:

Metformin

Dipeptidyl peptidase 4 (DPP-4) inhibitors

Glucagon-like peptide 1 (GLP-1) and dual GLP-1/gastric inhibitory peptide (GIP) receptor agonists

Sodium-glucose cotransporter 2 (SGLT2) inhibitors

Sulfonylureas

Thiazolidinediones (TZDs)

Metformin

Metformin (Glucophage) is classified as a biguanide medication and is the only available medication in this class. Metformin lowers blood glucose levels primarily by decreasing the amount of glucose produced by the liver. Metformin also helps lower blood glucose levels by making muscle tissue more sensitive to insulin so blood glucose can be used for energy.

It is usually taken two times a day. A side effect of metformin may be diarrhea, but this is improved when the drug is taken with food.

DPP-4 Inhibitors

DPP-4 inhibitors help improve A1C (a measure of average blood glucose levels over two to three months) without causing hypoglycemia (low blood glucose). They work by preventing the breakdown of naturally occurring hormones in the body, GLP-1 and GIP. These hormones reduce blood glucose levels in the body, but they are broken down very quickly so it does not work well when injected as a drug itself.

By interfering in the process that breaks down GLP-1 and GIP, DPP-4 inhibitors allow these hormones to remain active in the body longer, lowering blood glucose levels only when they are elevated. DPP-4 inhibitors do not cause weight gain and are usually very well tolerated.

There are four DPP-4 inhibitors currently on the market in the U.S.:

Alogliptin (Nesina)

Linagliptin (Tradjenta)

Saxagliptin (Onglyza)

Sitagliptin (Januvia)

GLP-1 and Dual GLP-1/GIP Receptor Agonists

As noted in the description for DPP-4 inhibitors, GLP-1 and GIP are natural hormones in the body that help maintain glucose levels. Use of GLP-1 and dual GLP-1/GIP receptor agonists is another strategy to help use these hormones to improve blood glucose management in people with type 2 diabetes.

These medications have similar effects to the GLP-1 and GIP produced in the body but are resistant to being broken down by the DPP-4 enzyme. These medications can result in large benefits on lowering blood glucose and body weight. Some agents in this class have also been shown to prevent heart disease. Most of these medications are injected, with the exception of one that is taken by mouth once daily, called semaglutide (Rybelsus).

Injectable GLP-1 receptor agonists currently on the market include:

Dulaglutide (Trulicity)

Exenatide (Byetta)

Exenatide extended-release (Bydureon)

Liraglutide (Victoza)

Lixisenatide (Adlyxin)

Injectable semaglutide (Ozempic)

One dual GLP-1/GIP receptor agonist is currently on the market called tirzepatide (Mounjaro). How often you need to inject these medications varies from twice daily to once weekly, depending on the medication. The most common side effect with these medications is nausea and vomiting, which is more common when starting or increasing the dose.

SGLT2 Inhibitors

Glucose in the bloodstream passes through the kidneys where it can either be excreted in the urine or reabsorbed back into the blood. Sodium-glucose cotransporter 2 (SGLT2) works in the kidney to reabsorb glucose. A new class of medication, SGLT2 inhibitors, block this action, causing excess glucose to be eliminated in the urine.

By increasing the amount of glucose excreted in the urine, people can see improved blood glucose, some weight loss, and small decreases in blood pressure. Bexagliflozin (Brenzavvy), canagliflozin (Invokana), dapagliflozin (Farxiga), and empagliflozin (Jardiance) are SGLT2 inhibitors that have been approved by the Food and Drug Administration (FDA) to treat type 2 diabetes. SGLT2 inhibitors are also known to help improve outcomes in people with heart disease, kidney disease, and heart failure.

For this reason, these medications are often used in people with type 2 diabetes who also have heart or kidney problems. Because they increase glucose levels in the urine, the most common side effects include genital yeast infections.

Sulfonylureas

Sulfonylureas have been in use since the 1950s and they stimulate beta cells in the pancreas to release more insulin. There are three main sulfonylurea drugs used today, glimepiride (Amaryl), glipizide (Glucotrol and Glucotrol XL), and glyburide (Micronase, Glynase, and Diabeta). These drugs are generally taken one to two times a day before meals.

All sulfonylurea drugs have similar effects on blood glucose levels, but they differ in side effects, how often they are taken, and interactions with other drugs. The most common side effects with sulfonylureas are low blood glucose and weight gain.

TZDs

Rosiglitazone (Avandia) and pioglitazone (Actos) are in a group of drugs called thiazolidinediones. These drugs help insulin work better in the muscle and fat and reduce glucose production in the liver.

A benefit of TZDs is that they lower blood glucose without having a high risk for causing low blood glucose. Both drugs in this class can increase the risk for heart failure in some individuals and can also cause fluid retention (edema) in the legs and feet.

[sophiareddy123]

The Oral Anti-Diabetic Drugs Market is segmented into drugs (Biguanides (Metformin), Alpha-glucosidase inhibitors, Dopamine-D2 receptor agonists (Bromocriptin (Cycloset)), Sodium-glucose Cotransport-2 (SGLT-2) inhibitor (Invokana (Canagliflozin), Jardiance (Empagliflozin), Farxiga/Forxiga (Dapagliflozin), and Suglat (Ipragliflozin)), Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (Januvia (Sitagliptin), Onglyza (Saxagliptin), Tradjenta (Linagliptin), Vipidia/Nesina (Alogliptin), and Galvus (Vildagliptin)), Sulfonylureas, and Meglitinides), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America). 

Download Free Sample Report - Oral Anti-Diabetic Drugs Market

[3cutpro]

Effective ways to fight surging healthcare costs

The United States health care currently stands at more than 17% of the GDP and sky is the limit. The budget of other countries are comparatively less on health care, but the trend is upwards. The continuous growth of the population and development of latest treatments constitute a significant factor behind the surge.

The healthcare cost can burn a hole in your pocket. According to research, the U.S can save approx. $1.3 trillion if the healthcare spending were at a comparable country average of 10% of the gross domestic product instead of 17%. The medical outcomes are no good if compared to other countries, and life expectancy in the country is slipping.

Today I’ll list down four practical ways to fight surging healthcare costs.

1.       Hospitals as last resort

Hospitals indeed aren’t the best place for healthcare. You should consider clinic or day surgery centers and not the expensive hospital operating theaters. If the situation is controllable, try getting advice over the phone itself or in person with your family doctor. Hospitals are a big shot and are incredibly expensive because the doctors and nurses offer many tests that might burn a hole down your pocket.

 2.       Review the screening tests

Screening tests can surely save lives by catching the disease pretty early and on a treatable stage. However, you shouldn’t rely on them. It’s better to review the test by yourself to check for some results that might be misleading. It’s suggested to question the screening test to be sure about it.

 3.       Pill cutting

Pill cutting technique has undoubtedly helped in current times to cut a significant amount. Heart disease medication like Entresto cost quite expensive. To cut it into equal halves so that it doesn’t lose its efficacy, you can rely on 3CutPro for it. This way, you can save dollars while cutting down on medication costs.

 4.       Paying cash

Doctors might take impressive incomes, but the offices are cash-poor. You’ll be in luck if you try paying in cash as it eliminates the need to file insurance claims and credit card transaction fees. Also, you can ask for a discount on your medication costs.

[mcatmemoranda]

I don't know brand names. Ugh.

Invokana = canagliflozin

Prilosec = omeprazole

[angrygoatgirl]

ICU Selfie

For those who don't know, I was in the ICU for a couple days earlier this week - diabetes related. ICU selfie! I'm doing better now though not completely out of the woods. Obviously it was awful, but it's also interesting. Some of you may know I have a tendency to get every rare, weird condition or side-effect that one can experience, but this one takes the cake: they have to contact the FDA and do a case study. Yay, I'm special! 🙃 Anyway, long story short, I'm going to be fine, if you're interested in the weird deets (my diabetic friends especially may want to read on), here they are:

My endocrinologist is always on top of the latest in diabetes treatments and tech. He even tipped me off to trying to get in the Faustman BCG vaccine trials. He is the absolute best endo I've ever had. My sugars are consistently just a little too high even with pump and CGM therapy, running between 180-250, with A1Cs between 7-8 mostly. There is a new trend of using type 2 drugs to help control difficult to control (sometimes called "brittle") type 1, and my endo gave me the type 2 med Invokana to try. The resident he's training is also type 1 and is on Invokana, and told me how much she loved it. On Friday 1/11 I took my first dose. My sugars instantly dropped to normal levels. The Invokana seemed great; it was keeping my sugars lower, reduced my insulin requirements by about 25-30%, and felt less aggressive than insulin.

Saturday things were still perfect with sugars between 80-135 all day, though I felt slightly fatigued. Fatigue is a known side-effect, though, so I dismissed it.

Sunday I felt a little weaker and more tired, and could smell a small amount of ketones in the back of my throat (ketones smell like a mixture of ammonia and fruit). My sugars were still perfect, hovering in the 120s most of the day. I was feeling somewhat queasy, so only managed to drink a V8 veggie juice. In the early evening I started experiencing more DKA symptoms, still with perfect blood sugars (and no other illness symptoms). In the afternoon I weighed myself and had lost about 4 pounds since the previous day -- yikes. I did a keto stick test and was spilling the max amount of ketones, as well as a moderate amount of glucose. My reasoning was that I hadn't eaten enough and so I was producing ketones. I ate some chili and crackers, felt a little better, asked my roommate (who was AMAZING through all this) to check on my later, and went to sleep.

At 11 my roommate checked on me and found me to be mostly coherent but sluggish and slurring my words. She called her father (who is a doctor, not just a random dude 😉), who reasoned the same as me: I hadn't eaten enough, and so was going into ketosis despite normal sugars. He recommended I eat protein and sugar, and if I didn't feel better go to the ER. After some juice and peanut butter I felt better and my speech was no longer slurred. I went to bed.

At 5am Monday morning I woke up and threw up pretty much everything I'd eaten the previous day. At this point the DKA was undeniable: short, labored breath, intense smell of ketones, and vomiting. My blood sugar was 95. NINETY FIVE! I asked my roommate to take me to the emergency room and was admitted to the ICU a few hours later. Poor, sweet Madison David will now forever have the image of me vomiting neon orange all over the Emergency Room floor imprinted upon her brain. 

Three days, two nights, five IV lines, and a shit ton of blood work (though thank god no catheter) later, I was out of DKA. ALL OF THE DOCTORS came to see me -- listening to groups of doctors discuss your condition amongst themselves while you're lying three feet away is always an experience -- my unusual case inspired such phrases as "This is unheard of", "We need to contact the drug company immediately", "We have to do a case study on this", "We'll have to get in touch with the FDA", etc.

I saw my endo yesterday (and maybe again today), who was extremely (though unnecessarily) apologetic -- but like everyone said, it was unheard of, so there's no way he could have known. He's now in touch with the hospital, took more blood, and we'll go from there. I'm still spilling ketones and glucose, and have lost almost 10 pounds this week -- not water weight, either. So...Invokana was an interesting bust, to say the least.

[siglerprescriptiondrugcards]

Canagliflozin

Brand Name: Invokana

Common Dosage Forms:

Tablets: 100 mg and 300 mg.

FDA Indications/Dosages:

As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus: Start with 100 mg before the first meal of the day. Dose can be increased to 300 mg once daily in patients who have an eGFR of 60 mL/min/1.73 m^2 or greater if greater glycemic control is needed and the 100 mg dose is tolerated. In patients with an eGFR between 45-60 mL/min/1.73 n^2, the maximum dose is 100 mg.

Monitor: RFT, Lipid Panel, K.

Pharmacology/Pharmacokinetics: Canagliflozin lowers blood glucose by inhibiting the sodium-glucose co-transporter 2 which is found in the proximal renal tubules and is responsible for the majority of reabsorption of filtered glucose from the tubular lumen. By reducing reabsorption of glucose from the tubular lumen and reducing the renal threshold for glucose, canagliflozin effectively increases urinary glucose excretion. It also appears to delay gastrointestinal glucose absorption and reduce postprandial glucose. Oral bioavailability is approximately 65% with no effect from the presence of food. However because of its effects on gastrointestinal glucose absorption, it is recommended to be taken before the first meal of the day. Metabolism occurs primarily via O-glucuronidation. The apparent half-life is between 10 to 13 hours depending on the dose. Excretion occurs primarily through the urine.

Drug Interactions: Canagliflozin does not affect the CYP enzyme system to any major degree. It does increase AUC and Cmax of digoxin by 20% and 36% at the 300 mg dose. Rifampin decreases canagliflozin AUC by 51%. Hyperkalemia may occur when used with potassium-sparing diuretics and ACE inhibitors.

Contraindication/Precautions: Contraindicated in patients with severe renal impairment (eGFR less than 30 mL/min/1.73 m^2), end stage renal disease (ESRD), or patients on dialysis. Use with caution in patients with renal impairment of eGFR less than 60 mL/min/1.73 m^2. Use with caution in the elderly, patients taking diuretics or medications that interfere with the renin-angiotensin-aldosterone system, and in patients with low systolic blood pressure due to potential for symptomatic hypotension. May cause ketoacidosis, hyperkalemia, elevated LDL-C, increased risk of bone fractures, and hypoglycemia in patients on insulin or insulin secretagogues. Use appropriate precautions and monitor for these conditions. Avoid use during pregnancy. Pregnancy Category D.

Adverse Effects: The most common adverse effects include urinary tract infections, genital mycotic infections, and increased urination. Less common adverse effects include increased thirst, constipation, nausea, and vulvovaginal pruritus. Infrequent but potentially severe adverse effects include systemic hypotension including dizziness and falls, increased risk of bone fractures, and hyperkalemia.

Patient Consultation:

Take before the first meal of the day.

Closely follow recommended diet and exercise recommendation.

It is important to monitor your blood glucose while taking this medication.

Contact a physician if the above side effects are severe or persistent.

Promptly report episodes of dizziness to your physician.

Keep well hydrated during therapy by drinking plenty of fluids.

Avoid excessive use of alcohol.

Avoid salt substitutes containing potassium.

Store in a cool, dry place away from sunlight and children.

If a dose is missed, take it as soon as possible. If it is closer to the time of your next dose than the dose you missed, skip the missed dose and return to your dosing schedule. Do not double doses.

[invokana411-blog]

If you have experienced complications after consuming Invokana, contact an experienced lawyer immediately. These cases are subject to the Statute of Limitations and have deadlines. A lawyer will examine your evidence carefully before determining if you can file litigation. They’ll also provide the most current Invokana lawsuit update to help you make a good decision.

[lea-naschkatze]

Visto primeiro no site: https://ift.tt/3bcDWeQ

[invokanaeffects-blog]

Did you experience serious health complications after taking Invokana or other SGLT2 inhibitors? Contact an Invokana lawyer now for a free, confidential legal consultation.

[invokanalawsuit72-blog]

Invokana was the first in a new class of drug for Type 2 diabetics and was declared to be effective for people to easily manage their diabetes without insulin by lowering blood sugar by causing the kidneys to remove the excess glucose from the body via urine. In March 2013, the FDA approved Invokana. Unfortunately, by May 2015 they were warning that Invokana may lead to devastating side effects.

[lawyersinusa-blog]

What is invokana lawsuit?

Continue reading for more information on Invokana lawsuits, or contact us today to speak with an experienced Invokana attorney about your potential.

If you or a loved one suffered a serious side effect while taking the drug Invokana, you may be able to seek financial compensation through an Invokana lawsuit. Our Invokana attorneys in USA are currently evaluating lawsuits for the following injuries:

– Diabetic ketoacidosis

– Kidney injury and kidney failure

– Heart attack

– Stroke

If you have questions about a potential Invokana lawsuit in USA, contact our attorneys today for a free case evaluation. We take pride in providing honest case evaluations and there is no obligation to sign with us if you call. If you think you may have a case, don’t wait—talk to an Invokana attorney today.

[mcatmemoranda]

Trulicity = dulaglutide

Avandia = rosiglitazone

Canagliflozin = Invokana

Dapagliflozin = Farxiga

Empagliflozin = Jardiance

Victoza = liraglutide

[mostlysignssomeportents]

6 years after expose revealed docs taking millions from pharma companies, it's only getting worse

In 2013, Propublica published an incredible story revealing how pharma giants laundered bribes to doctors in exchange for commitments to prescribe their expensive, proprietary and often dangerous products.

Six years later, the practice is worse than ever: "More than 2,500 physicians have received at least half a million dollars apiece from drugmakers and medical device companies in the past five years alone, a new ProPublica analysis of payment data shows. And that doesn’t include money for research or royalties from inventions. More than 700 of those doctors received at least $1 million."

Pharma's annual doctor-bribing spend is $2.1-$2.2b, distributed among about 600,000 docs out of the USA's 1.1m doctors every year. A spokesvillain for PHRMA, the pharmaceutical industry's lobbying arm, says that this proves that it's all OK, because if it was bad, PHRMA's members would have done less of it over time.

https://boingboing.net/2019/10/17/invokana-xarelto-eliquis-latud.html

[snowball-with-knives]

Ask my muse about their opinions or feelings about something, anon or not--and they’ll answer.  But only in gifs.